CCL22, CXCL9, CXCL10, CXCL11, CXCL13 (Approved for relapsing MS. α4 integrin antagonist, preventing leukocyte trafficking into the CNS. Reduces CSF levels of Th1 (CXCL9, CXCL10, CXCL11) and Th2 (CCL22) chemokines. Increases CXCR3-expressing B cells.) This evidence concerns the gene CXCL13 and myeloid sarcoma.